HBV-Induced Immune Imbalance in the Development of HCC

Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC. Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation and hepatocellular regeneration account for hepatocarcinogenesis. As a non-cytopathic virus, HBV is extensively recognized...

Full description

Bibliographic Details
Main Authors: Yongyan Chen, Zhigang Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02048/full
_version_ 1818839848717385728
author Yongyan Chen
Yongyan Chen
Zhigang Tian
Zhigang Tian
author_facet Yongyan Chen
Yongyan Chen
Zhigang Tian
Zhigang Tian
author_sort Yongyan Chen
collection DOAJ
description Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC. Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation and hepatocellular regeneration account for hepatocarcinogenesis. As a non-cytopathic virus, HBV is extensively recognized to mediate chronic liver damage through abnormal immune attack. However, the mechanisms driving HBV infection to HCC are poorly understood. During chronic HBV infection in humans, the adaptive immunity changes from immune tolerance to progressive immune activation, inactivation, reactivation and exhaustion, all of which may be the immune pathogenic factors for the development of HCC. Recently, the immunopathogenic mechanisms were described in mouse HBV-induced HCC models, which is absolutely dependent on the presence of HBV-specific T cell response and NK cell-derived IFN-γ, findings which are consistent with the observations from CHB and HCC patients. In this review, we summarize recent research progression on the HBV-specific CD8+ T cells, and also CD4+ T cells, B cells and non-specific immune cells and molecules underlying chronic HBV infection and eventual HCC development to demonstrate the pathogenesis of HBV-induced immune imbalance. Based on the progression, we discussed the potential of immune-based therapies and their challenges in the treatment of HBV-related HCC, including the checkpoint inhibition, genetically modified T cell transfer, therapeutic vaccines and metabolic modulation.
first_indexed 2024-12-19T04:00:49Z
format Article
id doaj.art-223fbb15cfa1411dba36123123fa1171
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-12-19T04:00:49Z
publishDate 2019-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-223fbb15cfa1411dba36123123fa11712022-12-21T20:36:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-08-011010.3389/fimmu.2019.02048478201HBV-Induced Immune Imbalance in the Development of HCCYongyan Chen0Yongyan Chen1Zhigang Tian2Zhigang Tian3Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences, University of Science and Technology of China, Hefei, ChinaInstitute of Immunology, University of Science and Technology of China, Hefei, ChinaHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences, University of Science and Technology of China, Hefei, ChinaInstitute of Immunology, University of Science and Technology of China, Hefei, ChinaChronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC. Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation and hepatocellular regeneration account for hepatocarcinogenesis. As a non-cytopathic virus, HBV is extensively recognized to mediate chronic liver damage through abnormal immune attack. However, the mechanisms driving HBV infection to HCC are poorly understood. During chronic HBV infection in humans, the adaptive immunity changes from immune tolerance to progressive immune activation, inactivation, reactivation and exhaustion, all of which may be the immune pathogenic factors for the development of HCC. Recently, the immunopathogenic mechanisms were described in mouse HBV-induced HCC models, which is absolutely dependent on the presence of HBV-specific T cell response and NK cell-derived IFN-γ, findings which are consistent with the observations from CHB and HCC patients. In this review, we summarize recent research progression on the HBV-specific CD8+ T cells, and also CD4+ T cells, B cells and non-specific immune cells and molecules underlying chronic HBV infection and eventual HCC development to demonstrate the pathogenesis of HBV-induced immune imbalance. Based on the progression, we discussed the potential of immune-based therapies and their challenges in the treatment of HBV-related HCC, including the checkpoint inhibition, genetically modified T cell transfer, therapeutic vaccines and metabolic modulation.https://www.frontiersin.org/article/10.3389/fimmu.2019.02048/fullHBVimmune dysfunctionHCCadaptive immunityinnate immunity
spellingShingle Yongyan Chen
Yongyan Chen
Zhigang Tian
Zhigang Tian
HBV-Induced Immune Imbalance in the Development of HCC
Frontiers in Immunology
HBV
immune dysfunction
HCC
adaptive immunity
innate immunity
title HBV-Induced Immune Imbalance in the Development of HCC
title_full HBV-Induced Immune Imbalance in the Development of HCC
title_fullStr HBV-Induced Immune Imbalance in the Development of HCC
title_full_unstemmed HBV-Induced Immune Imbalance in the Development of HCC
title_short HBV-Induced Immune Imbalance in the Development of HCC
title_sort hbv induced immune imbalance in the development of hcc
topic HBV
immune dysfunction
HCC
adaptive immunity
innate immunity
url https://www.frontiersin.org/article/10.3389/fimmu.2019.02048/full
work_keys_str_mv AT yongyanchen hbvinducedimmuneimbalanceinthedevelopmentofhcc
AT yongyanchen hbvinducedimmuneimbalanceinthedevelopmentofhcc
AT zhigangtian hbvinducedimmuneimbalanceinthedevelopmentofhcc
AT zhigangtian hbvinducedimmuneimbalanceinthedevelopmentofhcc